Trial · NCT04518995
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24 | Week 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24 | Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of responders | NUMBER |
| SECONDARY | Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20 | Weeks 4, 8, 12, 16, and 20 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of participants | NUMBER |
| SECONDARY | Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24 | Baseline, Weeks 4, 8, 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | percent change | MEAN |
| SECONDARY | Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24 | Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of responders | NUMBER |
| SECONDARY | Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24 | Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of responders | NUMBER |
| SECONDARY | Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24 | Baseline, Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24 | Baseline, Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24 | Baseline, Weeks 12, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of participants | NUMBER |
| SECONDARY | Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24 | Baseline, Weeks 12, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24 | Baseline, Weeks 12, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24 | Baseline, Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24 | Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of participants | NUMBER |
| SECONDARY | Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24 | Baseline, Weeks 12, 16, 20, and 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24 | Baseline and Week 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. Overall number of participants analyzed indicates the number of participants with data available for analysis of this outcome measure. Number of participants analyzed indicates the number of participants with data available for analysis at the specified timepoint. | score on a scale | MEAN |
| SECONDARY | Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24 | Week 24 | Efficacy population included all participants who were randomized in the study and dispensed study drug during the treatment period. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04518995/outcomes